REPL · Replimune Group, Inc. · Executive Compensation
$11.85
+0.13 (+1.11%)
At close · Oct 22
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.10B
Shares
94.22M
Volume · Oct 22
944.36K
Avg daily vol (3M)
3.99M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Sushil Patel | Chief Executive Officer | $3,697,661 |
| Konstantinos Xynos | Chief Medical Officer | $1,624,865 |
| Emily Hill | Chief Financial Officer | $1,594,953 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Emily Hill | Chief Financial Officer | $3,383,157 |
| Konstantinos Xynos | Chief Medical Officer | $2,448,364 |
| Sushil Patel | Chief Executive Officer | $2,063,097 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Philip Astley-Sparke | Chief Executive Officer | $3,646,550 |
| Jean Franchi | Chief Financial Officer and Treasurer | $2,608,123 |
| Sushil Patel | Chief Strategy Officer | $2,595,003 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sushil Patel | Chief Strategy Officer | $6,952,619 |
| Philip Astley-Sparke | Chief Executive Officer | $6,366,277 |
| Robert Coffin | President and Chief Research & Development Officer | $5,722,547 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Andrea Pirzkall | Chief Medical Officer | $4,726,571 |
| Robert Coffin | President and Chief Research & Development Officer | $2,457,592 |
| Philip Astley-Sparke | Chief Executive Officer | $2,457,592 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Coffin | President and Chief Research & Development Officer | $2,934,145 |
| Philip Astley-Sparke | Chief Executive Officer | $2,155,164 |
| Jean Franchi | Chief Financial Officer | $1,802,202 |
| Howard Kaufman | Former Chief Medical Officer | $1,274,660 |
| Pamela Esposito | Chief Business Officer | $1,227,437 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert Coffin | President and Chief Research & Development Officer | $2,265,737 |
| Howard Kaufman | Former Chief Medical Officer | $1,875,600 |
| Philip Astley-Sparke | Chief Executive Officer | $1,812,591 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Goller | member of the Board | Appointed | 2025-03-07 |
| Paul Bullock | chief manufacturing officer | Appointed | 2024-03-26 |
| Dr. Colin Love | chief operating officer | Retired | 2024-03-26 |
| Dieter Weinand | lead independent director of the Board | Appointed | 2024-03-26 |
| Philip Astley-Sparke | executive chairman of the Board | Appointed | 2024-03-26 |
| Dr. Sushil Patel | Class III director | Appointed | 2024-03-26 |
| Dr. Sushil Patel | chief executive officer | Appointed | 2024-03-26 |
| Emily Hill | Chief Financial Officer | Appointed | 2023-09-19 |
| Veleka Peeples-Dyer | member of the Board | Appointed | 2023-06-05 |
| Andrew Schwendenman | Chief Accounting Officer | Appointed | 2023-05-18 |
| Jean Franchi | Chief Financial Officer | Resigned | 2023-05-18 |
Leadership
- Dr. Sushil Patel CEO, Board Member
- Sushil Patel CEO, Board Member
- Dieter Weinand Chairman, Board Member
- Philip Astley-Sparke Chairman
- Emily Hill CFO
- Andrew Schwendenman Chief Accounting Officer
- Christy Oliger Board Member
- Joseph Slattery Board Member
- Kapil Dhingra Board Member
- Madhavan Balachandran Board Member
- Michael Goller Board Member
- Paolo Pucci Board Member
- Tanya Lewis Board Member
- Veleka Peeples-Dyer Board Member
Key facts
CIK
1737953
CUSIP
76029N106
13F (30d)
19 filings
19 filers
Visit website
Investor relations